 price
tough start new year
wba began weaker-than-expect rx
growth compound broader reimburs
headwind look forward guid
ep bonu payment
contract true-up although true-up time issu
larg revers result
today earn increas investor uneas regard
long-term profit profil compani push
prospect ep like
also despit impact wba broader cost cut
initi ramp cours
consequ broadli take number
gross margin pressur partial off-set
continu opex manag produc
continu albeit moder margin declin
oper incom declin forecast period plu
benefit ep share repurchas given
profil maintain line rate lower
price target equat
price-to-earnings ebitda
continu confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
soften condit uk
progress four strateg initi
move data resourc cloud
progress develop new servic
digit compani
yoy comp impact one-tim item includ one-tim bonu payment
retail pharmaci intern impact challeng uk environ
manag program
improv core trend headwind includ bonu impact lap prior supplier
suplier fund reimburs
declin sg asav offset hw
advers item declin op incom
lower pharmaci retail gp
continu brand inflat script volum growth
improv growth recent week sale
cigarett exit larger impact go forwardaround ep impact year
tw cough cold flu
time prior year supplier fund hire shrink
uk chile impact
higher nh reimburs level increas sale servic lower script volum
overal held market share
led em uk
chang custom contract help uk
lap impact contract chang
jv ep accret
work capit initi track
extend payment term healthi level
procur activ
smart organizationtransform oper get leaner
implement global busi initi
walgreen store closur
head quarter cost reduct mexico chile thailand
complet boot uk closur
new small store us
select consult firm pharmaci oper system
partnership posit result far
gpo allianc decemb
primari care store houston
jenni craig locat end januari
patient resourc center store
strong perform retail app download yoy
rebalanc retail space uk store
line expect
solid progress market
partnership offer omnichannel uk ireland
beat hundr million
tcmp well ahead track
deal german pharma market critic
strong momentum decemb
script growth solid msd growth month decemb
script growth must growth hit target
overhead becom signific driver
combo inflat volum increment invest
slight favor tax benefit
slightli less come gp
off-set script under-deliveri
anticip hold market share prime
work well independ blue
great relationship prime expand specialti
reimburs impact
refer
highlight due reimburs time bonu payment
contract april may june timelin
contract true prior year
difficult forecast reimburs
stabil payment nih side
take action becom profit
lost volum much expect
consolid acceler vertic horizont
pbm put pressur market better price
mitig pressur cost program
lost access network summer
medicar well
less well aet
pleas renew contract prime
brand inflat procur
saw brand inflat read seem deflat gener
outperform vs rangemsd-hsd term cost reduct
villagemd houston end februari
track
end quarter
np score expect
data cloud
allow pharmacist drive valu
other follow unit lead
effect provid relief alreadi
unit pdp
alreadi earn money back
 pharmaci slightli belowgav script
margin expect
work well oper uk
invest new pharmacist
year recoveri last year difficulti
profit pharmaci need improv enabl reinvest
rough quarter retail
script volum might go slightli
half one-tim advers item
decemb start extrem slow last two week extrem strong
small network chang mid-year vast major contract well
line sight year
wait dust settl
substanti sale growth product high-teen number store
checkpoint rel strategi
work partner conveni model
strong footprint america
capital-expenditure expens
take friction system remov cost rais revenu
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti on-line competit amazon erod front end comp margin us
pharmaci share continu reimburs pressur us eu hit ultim lead total margin compress
transact prove challeng increas volum /revenu store appear futil lead poor return
posit independ retail us becom disadvantag vertic integr peer capabl take notabl
share manag unabl locat creativ transact leav balanc sheet underutil limit total oper
growth beauti push ultim becom distract momentum build manag must revisit costli rebuild
articl articl
time dissemin januari
analyst elizabeth anderson suzi yoon amato primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
